DK2696848T3 - Frysetørrede nanosuspensioner af lægemiddel - Google Patents

Frysetørrede nanosuspensioner af lægemiddel Download PDF

Info

Publication number
DK2696848T3
DK2696848T3 DK12713187.8T DK12713187T DK2696848T3 DK 2696848 T3 DK2696848 T3 DK 2696848T3 DK 12713187 T DK12713187 T DK 12713187T DK 2696848 T3 DK2696848 T3 DK 2696848T3
Authority
DK
Denmark
Prior art keywords
nanosus
suspensions
freeze
dried
medicinal products
Prior art date
Application number
DK12713187.8T
Other languages
English (en)
Inventor
Sabine Karine Katrien Inghelbrecht
Henning Gieseler
Jakob Andreas Beirowski
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK2696848T3 publication Critical patent/DK2696848T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK12713187.8T 2011-04-15 2012-04-13 Frysetørrede nanosuspensioner af lægemiddel DK2696848T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161475811P 2011-04-15 2011-04-15
PCT/EP2012/056818 WO2012140220A1 (en) 2011-04-15 2012-04-13 Freeze dried drug nanosuspensions

Publications (1)

Publication Number Publication Date
DK2696848T3 true DK2696848T3 (da) 2020-10-12

Family

ID=45937395

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12713187.8T DK2696848T3 (da) 2011-04-15 2012-04-13 Frysetørrede nanosuspensioner af lægemiddel

Country Status (21)

Country Link
US (5) US20140038996A1 (da)
EP (2) EP3799860A1 (da)
JP (1) JP6161593B2 (da)
CN (2) CN103764117A (da)
AU (1) AU2012241726C1 (da)
BR (1) BR112013026363B1 (da)
CA (1) CA2832410C (da)
CY (1) CY1123434T1 (da)
DK (1) DK2696848T3 (da)
ES (1) ES2823805T3 (da)
HK (1) HK1257447A1 (da)
HR (1) HRP20201241T1 (da)
HU (1) HUE050970T2 (da)
LT (1) LT2696848T (da)
MX (1) MX362344B (da)
PL (1) PL2696848T3 (da)
PT (1) PT2696848T (da)
RS (1) RS60651B1 (da)
RU (1) RU2643062C2 (da)
SI (1) SI2696848T1 (da)
WO (1) WO2012140220A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3024230C (en) * 2011-04-28 2022-10-18 Oncopeptides Ab Lyophilized preparation of cytotoxic dipeptides
MX365205B (es) 2012-10-26 2019-05-27 Oncopeptides Ab Preparaciones liofilizadas de melfalán flufenamida.
KR102121404B1 (ko) * 2013-03-15 2020-06-11 썬 파마 글로벌 에프제트이 아비라테론 아세테이트 제제
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
HUP1500055A1 (hu) * 2015-02-09 2016-08-29 Druggability Technologies Ip Holdco Ltd Abirateron acetát komplexei, eljárás elõállításukra, és az azokat tartalmazó gyógyászati készítmények
CN105902496B (zh) * 2016-04-18 2019-10-25 沈阳药科大学 一种纳米混悬液固体化过程的处理方法
US10507165B2 (en) * 2017-05-31 2019-12-17 Adienne Pharma & Biotech Sa Multi chamber flexible bag and methods of using same
RU2665383C9 (ru) * 2017-06-22 2019-07-23 Общество с ограниченной ответственностью "Вириом" Фармацевтическая наносуспензия для терапии ВИЧ-инфекции
SI3651736T1 (sl) 2017-07-14 2021-11-30 Janssen Pharmaceutica Nv Formulacije z dolgim delovanjem
RU2721562C1 (ru) * 2019-06-04 2020-05-20 Автономная некоммерческая образовательная организация высшего образования "Сколковский институт науки и технологий" Способ загрузки неорганических наночастиц или органических молекул в пористые частицы микронного или субмикронного размера
CN111149795A (zh) * 2020-01-14 2020-05-15 成都艾伟孚生物科技有限公司 一种冷冻保护剂及其应用和一种***冷冻液及其制备方法
CN113440529B (zh) * 2020-03-25 2023-11-14 江苏恒瑞医药股份有限公司 一种可注射的药物组合物及其制备方法
WO2021222545A1 (en) * 2020-04-29 2021-11-04 The Texas A&M University System Naloxone nanoparticle compositions and methods thereof
WO2022008643A1 (en) 2020-07-09 2022-01-13 Janssen Pharmaceutica Nv Long-acting formulations
CA3184868A1 (en) 2020-07-09 2022-01-13 Rene Holm Long-acting formulations
CA3182854A1 (en) 2020-07-09 2022-01-13 Rene Holm Long-acting formulations
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine
JP6886551B1 (ja) * 2020-11-06 2021-06-16 医療法人祥和会 歯科用の局所麻酔液
CN112641950B (zh) * 2021-01-12 2022-12-16 北京德立福瑞医药科技有限公司 含有难溶性抗肿瘤活性剂的药物组合物及其制备方法
WO2023108156A1 (en) * 2021-12-11 2023-06-15 Beloteca, Inc. Ziprasidone formulations
WO2023154454A1 (en) * 2022-02-10 2023-08-17 Soligenix, Inc. Telmisartan nanosuspension for therapy of respiratory infections and methods of making and using same
WO2023203255A1 (en) * 2022-04-22 2023-10-26 Janssen Sciences Ireland Unlimited Company Freeze dried compositions
WO2024068699A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
CN116115621A (zh) * 2022-10-31 2023-05-16 广州鹏兴医药科技有限公司 氢***组合物及其制备方法及氢***微针透皮贴剂
CN116919898B (zh) * 2023-09-15 2023-12-19 北京星辉再生科技有限责任公司 米诺地尔纳晶混悬液组合物、米诺地尔纳晶混悬液及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
FR2740686B1 (fr) 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
US20050004049A1 (en) 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
EP1569623B1 (en) 2002-12-13 2008-10-15 Jagotec Ag A topical nanoparticulate spironolactone formulation
RU2331424C2 (ru) * 2002-12-13 2008-08-20 Джеготек Аг Топический состав, содержащий наночастицы спиронолактона
KR20070119678A (ko) * 2005-04-13 2007-12-20 화이자 프로덕츠 인코포레이티드 지속 방출되는 나노입자 조성물을 제공하기 위한주사가능한 저장소 제제 및 방법
CA2631714C (en) * 2005-12-02 2014-09-16 Novartis Ag Nanoparticles for use in immunogenic compositions
SI2040671T1 (en) * 2006-06-23 2018-05-31 Janssen Sciences Ireland Uc Water suspensions TMC278
US20100003332A1 (en) * 2006-07-27 2010-01-07 Amorepacific Corporation Process For Preparing Powder Comprising Nanoparticles of Sparingly Soluble Drug
CL2008000746A1 (es) * 2007-03-14 2008-09-22 Tibotec Pharm Ltd Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
ES2437331T3 (es) * 2007-07-12 2014-01-10 Janssen R&D Ireland Forma cristalina de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo
US8161810B2 (en) 2008-01-29 2012-04-24 Carefusion 303, Inc. Syringe imaging systems
CN101283982B (zh) * 2008-06-03 2010-06-02 南京工业大学 非诺贝特纳米混悬剂及其制备方法
CN101904820A (zh) * 2009-06-02 2010-12-08 姜玲敏 槲皮素纳米混悬剂冻干组合物及其制备方法和应用
CN101612131B (zh) * 2009-07-17 2011-09-14 郑州大学 2-甲氧基***纳米混悬剂冻干粉及其制备方法
CN101953808B (zh) * 2010-10-13 2013-03-13 厦门大学 抗肿瘤化合物去乙酰真菌环氧乙酯注射剂及其制备方法

Also Published As

Publication number Publication date
US11389448B2 (en) 2022-07-19
HUE050970T2 (hu) 2021-01-28
BR112013026363A2 (pt) 2016-12-27
MX2013011985A (es) 2013-11-04
US20140038996A1 (en) 2014-02-06
ES2823805T3 (es) 2021-05-10
CN108210469A (zh) 2018-06-29
AU2012241726A1 (en) 2013-10-24
CA2832410A1 (en) 2012-10-18
US20190076428A1 (en) 2019-03-14
JP6161593B2 (ja) 2017-07-12
US20220409616A1 (en) 2022-12-29
US10166231B2 (en) 2019-01-01
RU2013150803A (ru) 2015-05-20
WO2012140220A1 (en) 2012-10-18
PL2696848T3 (pl) 2020-12-28
CY1123434T1 (el) 2021-12-31
EP2696848A1 (en) 2014-02-19
SI2696848T1 (sl) 2020-10-30
US11819502B2 (en) 2023-11-21
BR112013026363B1 (pt) 2021-10-13
MX362344B (es) 2019-01-11
US20240148726A1 (en) 2024-05-09
RS60651B1 (sr) 2020-09-30
HRP20201241T1 (hr) 2020-11-27
US20160317534A1 (en) 2016-11-03
CA2832410C (en) 2019-07-23
AU2012241726C1 (en) 2017-09-14
EP3799860A1 (en) 2021-04-07
CN103764117A (zh) 2014-04-30
LT2696848T (lt) 2020-09-10
JP2014515021A (ja) 2014-06-26
EP2696848B1 (en) 2020-07-22
HK1257447A1 (zh) 2019-10-18
PT2696848T (pt) 2020-09-03
AU2012241726B2 (en) 2017-04-27
RU2643062C2 (ru) 2018-01-30

Similar Documents

Publication Publication Date Title
DK2696848T3 (da) Frysetørrede nanosuspensioner af lægemiddel
DK2765990T3 (da) Faststofdispersion
CO6930350A2 (es) Mezclas de cemento-scm de partículas empacadas
DK2694038T3 (da) Farmaceutisk sammensætning
DK2771364T3 (da) Fremstilling af heterodimere proteiner
BR112014003052A2 (pt) composições farmacêuticas
SMT201600410B (it) Modulatori diidropirazolici di gpr40
CO6880066A2 (es) Composición farmacéutica de sabor enmascarado
CO6960555A2 (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
AR092198A1 (es) Derivados de pirazolopirimidinas
DK2846809T3 (da) Behandling af myelosuppression
CO6990717A2 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
CO6930367A2 (es) Composiciones farmaceúticas
BR112014013850A2 (pt) conjunto de prateleiras
CO6940426A2 (es) Formulaciones farmacéuticas
DK2925338T3 (da) Frysetørret formulering af tat-nr2b9c
DK2897594T3 (da) Farmaceutisk sammensætning
DK2894998T3 (da) Rotation af kegle
BR112014009319A2 (pt) compostos farmacêuticos
CO6940377A2 (es) Formulaciones de liofilizadas de fgf-18
BR112014015885A8 (pt) preparação farmacêutica
FR2995524B1 (fr) Prothese endo-urinaire
DK2838850T3 (da) Oprensning af titantetrachlorid
ES1080381Y (es) Fachada de medios
DK2928896T3 (da) Fast form af dihydro-pyrido-oxazin-derivat